The Pharmaceutical Manufacturers Association announces on Dec. 15 that it will establish a formal policy position on the Uruguay Round of international trade talks when the association's board meets Jan. 20. Regarding the negotiations concluded Dec. 15 on the General Agreement on Tariffs and Trade, PMA notes that the agreement retains the 20-year patent term, which the association supports, but leaves "two major concerns" unresolved: a 10-year grace period for countries that currently do not provide intellectual property protection and denial of patent protection for products currently in the development pipeline....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth